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STATE-OF-THE-ART REVIEW2013 ACC/AHA Guideline Recommends
Fixed-Dose Strategies Instead of
Targeted Goals to Lower Blood Cholesterol
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MaThe American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines recently
issued the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk
in Adults. This new guideline endorses a paradigm shift in strategies for reducing atherosclerotic cardiovascular disease
(ASCVD) events by lowering blood cholesterol. Whereas previous guidelines focused on therapy to decrease low-density
lipoprotein and non–high-density lipoprotein cholesterol to speciﬁc target levels, the new guideline instead proposes
implementation of cholesterol-lowering treatment using evidenced-based intensity of statin therapy without such
targets. The guideline also provides a new risk estimator for primary prevention decisions, including stroke outcomes and
data on African Americans, which will signiﬁcantly increase the number of patients recommended for outcome-related
beneﬁts of cholesterol-lowering therapy. The ﬁrst section of this paper reviews the process by which the task force
developed the new evidence-based guideline, the major ﬁndings and recommendations, and their implications. The
second section primarily focuses on the question of how much low-density lipoprotein cholesterol should be lowered and
on additional considerations in risk assessment. (J Am Coll Cardiol 2014;64:601–12) © 2014 by the American College of
Cardiology Foundation.CHOLESTEROL GUIDELINES:
FOLLOWING THE EVIDENCE
Sidney C. Smith, Jr., MD
BACKGROUND. Almost one-third of the population
in the United States will die as a result of heart attack
or stroke associated with atherosclerotic cardiovas-
cular disease (ASCVD), the leading cause of death and
disability in our country today (1). The major treatable
causes of ASCVD include hypercholesterolemia, hy-
pertension, diabetes, and an unhealthy lifestyle
associated with tobacco consumption, poor diet, lack
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cholesterol in at-risk populations. To update the
previous guideline recommendations issued by the
Adult Treatment Panel III in 2001 (2), the National
Heart, Lung, and Blood Institute (NHLBI) convened a
panel in 2008 to review the evolving evidence base
from RCTs regarding treatment of blood cholesterol.
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ABBR EV I A T I ON S
AND ACRONYMS
ABI = ankle-brachial index
ACC = American College of
Cardiology
AHA = American Heart
Association
ASCVD = atherosclerotic
cardiovascular disease
CAC = coronary artery calcium
CQ = critical question
FH = familial
hypercholesterolemia
HDL-C = high-density
lipoprotein cholesterol
hsCRP = high-sensitivity
C-reactive protein
LDL-C = low-density
lipoprotein cholesterol
NHLBI = National Heart, Lung,
and Blood Institute
RCT = randomized controlled
trial
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rotic Cardiovascular Risk in Adults (2), is
strongly focused on RCT-related evidence.
This has resulted not only in a new perspec-
tive on treatment strategies, but also in a new
paradigm focusing on proven therapy, rather
than arbitrary low-density lipoprotein
cholesterol (LDL-C) and/or non–high-density
lipoprotein cholesterol (HDL-C) targets.
PROCESS. These new guidelines for the
treatment of blood cholesterol are distin-
guished by: 1) an exclusive focus on evidence
derived from the systematic review of RCTs;
2) a guideline panel with broad expertise
appointed by the NHLBI, composed of 13
members and 3 ex-ofﬁcio members from pri-
mary care, cardiology, epidemiology, clinical
lipidology, and endocrinology; and 3) a re-
striction to develop guideline recommenda-
tions on the basis of evidence review from 3
critical questions (CQs) developed by the
guideline committee.The guideline process was conducted along lines
consistent with recommendations made by the
Institute of Medicine (3). Indeed, an analysis of
the durability of ACC/AHA Class I recommendations
indicates that downgrades, reversals, and omissions
were more likely among recommendations not
supported by multiple RCTs (4). For each of the 3
CQs, an independent contractor performed a sys-
tematic review of the published data restricted to
RCTs published in English from January 1, 1995,
through December 1, 2009. Major RCTs and meta-
analyses of RCTs published through July 2013
were included in the expert panel’s discussion of
recommendations.
This process differs signiﬁcantly from that associ-
ated with previous guideline recommendations in
that no observational studies are included and
hard clinical endpoints of ASCVD are required for an
RCT to be considered in the evidence base. For this
report, ASCVD included coronary heart disease,
stroke, and peripheral arterial disease of presumed
atherosclerotic origin. Importantly, studies with out-
comes of surrogate markers, such as LDL-C, other
lipids, or biomarkers, were not included for consid-
eration. Only RCTs with hard clinical outcomes were
used as evidence for recommendations in the new
guidelines.
Evidence tables were developed and evidence
statements were decided upon by the expert panel
and rated according to strength of evidence. On the
basis of the evidence tables, the panel made guidelinerecommendations, graded according to strength of
evidence. The panel was limited to the 3 CQs
considered of the greatest importance to the devel-
opment of guidelines for the treatment of blood
cholesterol. This was also true of the Risk Assessment
(5) and Lifestyle Guideline Panels (6) that were part of
the same process. The CQs that governed the sys-
tematic review upon which the guideline recom-
mendations are as follows:
CQ1 : What i s the ev idence for LDL-C and non–
HDL-C goals for the secondary prevent ion of
ASCVD? In a review of 19 RCTs, no data supporting
treatment or titration of cholesterol-lowering therapy
to a speciﬁc LDL-C or non–HDL-C goal in adults with
clinical ASCVD were found. Fixed-dose strategies
using statin therapy were used in the majority of tri-
als showing improved clinical outcomes. Speciﬁcally,
the expert panel was unable to ﬁnd any RCTs that
evaluated treatment of all patients in a treatment
group to speciﬁc treatment goals of <100
or <70 mg/dl.
CQ2: What i s the ev idence for LDL-C and non–
HDL-C goals for the pr imary prevent ion of
ASCVD? In a review of 6 RCTs in patients without
clinical ASCVD, ﬁxed-dose strategies, rather than a
treat-to-target strategy, were used to conﬁrm the
efﬁcacy of cholesterol-lowering therapy to prevent
ASCVD. None of the RCTs considered for CQ1 and
CQ2 compared statin therapy titrated to 1 or another
LDL-C or non–HDL-C goal.
CQ3: For pr imary and secondary prevent ion ,
what i s the impact on l ip id leve ls , e f fect iveness ,
and safety of spec iﬁc cholestero l -modi fy ing
drugs used for l ip id management in genera l
and in se lected subgroups? Therapeutic inter-
ventions reviewed involved single-dose or combina-
tion therapies for lowering cholesterol including
statins, ﬁbrates, nicotinic acid, bile acid sequestrants,
ezetimibe, and omega-3 fatty acids. Information from
CQ3 was included with that from CQ1 and CQ2
for recommendations regarding cholesterol-lowering
drugs for primary and secondary prevention of
ASCVD.
A thorough review of the methods and results of
the evidence reviewed may be found in the guideline
(2) and in the NHLBI evidence report (7).
MAJOR FINDINGS AND RECOMMENDATIONS. To
develop guideline recommendations, the results from
the systematic review conducted by this panel were
supplemented by those from the Risk Assessment
Working Group (5) and the Lifestyle Management
Panel (6), initially in a format developed by the NHLBI
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603(2). After the NHLBI announced its intent to publish
the guidelines via a collaborative arrangement with
the ACC and the AHA (8), the guideline recom-
mendations were translated into the ACC/AHA
guideline recommendation format (2). This process
also occurred with the Risk Assessment and Lifestyle
Guidelines, published at the same time. A list of the
major guideline recommendations may be found in
Figure 1, and a complete summary has been published
as the 2013 ACC/AHA Guideline on the Treatment of
Blood Cholesterol to Reduce Atherosclerotic Cardio-
vascular Risk in Adults (2).
The major ﬁndings and recommendations in the
new guideline are as follows:
Adherence to a hea l thy l i festy le . The panel
unanimously endorsed the report of the 2013 ACC/
AHA Lifestyle Management Guideline (6), which
endorses a DASH (Dietary Approaches to Stop Hy-
pertension) or Mediterranean-style diet (A diet high
in vegetables, fruits, low-fat dairy products, whole
grains, poultry, ﬁsh, and nuts; and low in sweets,
sugar-sweetened beverages, and red meats. Also, it
includes foods that are low in saturated fat, total
fat, and cholesterol but rich in potassium, magne-
sium, and calcium as well as protein and ﬁber.) The
guideline also stresses the importance of daily aer-
obic physical activity, avoidance of the use of to-
bacco products, and maintenance of a healthy body
weight. Patients should be checked periodically for
hypertension and diabetes and be treated appro-
priately. The importance of a healthy lifestyle
cannot be overemphasized, and its beneﬁts should
be stressed to all patients being seen for both pri-
mary and secondary prevention during their regular
visits.
Beneﬁ ts of stat in therapy for 4 pat ient groups .
The systematic review of RCTs found strong evidence
for the beneﬁts of statin therapy to reduce cardio-
vascular events and improve outcomes in 4 patient
groups (Central Illustration), which included those
with:
 Established clinical ASCVD (secondary prevention);
 Primary elevation of LDL-C levels $190 mg/dl;
 diabetes, age 40 to 75 years, who have LDL-C levels
70 to 189 mg/dl; and
 primary prevention without diabetes, age 40 to
75 years, with an estimated 10-year risk $7.5%.
Evidence of moderate strength was found to sup-
port statin therapy for primary prevention when the
10-year ASCVD risk was $5% to 7.5%.
Review of evidence from RCTs failed to show
consistent beneﬁt when statin therapy was started in: Patients undergoing maintenance hemodialysis; or
 Patients in New York Heart Association functional
classes II to IV.
Thus, no recommendation was made regarding the
initiation or continuation of statin therapy in these
patients.
Use of r i sk est imator for pr imary prevent ion.
The Framingham risk assessment tool did not include
stroke as an endpoint and did not have a separate
risk equation for African-American men and women.
A new pooled cohort risk estimator was developed
to assist with decisions regarding lowering blood
cholesterol for primary prevention by the Risk
Assessment Work Group (5). This risk estimator for
10-year ASCVD events has been expanded from the
previous endpoint of hard congenital heart disease
(nonfatal myocardial infarction and congenital heart
disease) recommended by the Adult Treatment Panel
III to include ﬁrst occurrence of stroke (nonfatal and
fatal) along with myocardial infarction (nonfatal and
fatal). Pooled cohort equations for the risk estimator
were developed from 5 NHLBI-sponsored longitudi-
nal population-based cohorts of African-American
and white men and women (ARIC [Atherosclerotic
Risk in Communities]), CHS [Cardiovascular Health
Study], CARDIA [Coronary Artery Risk Development
in Young Adults], and the original Framingham Heart
Study and its offspring cohorts). These pooled cohort
equations were then validated in the contemporary
cohorts of MESA (Multi-Ethnic Study of Atheroscle-
rosis) and REGARDS (Reasons for Geographic and
Racial Differences in Stroke). The equations are
applicable to non-Hispanic, white, and African-
American men and women age 40 to 79 years with
LDL-C levels of 70 to 189 mg/dl. Data from the
REGARDS study (9) are especially important because
it is a community-based study appropriate to the
United States population. It conﬁrms the use of these
pooled risk equations in the populations for which
they are designed.
It is important to emphasize that this risk estimator
should be used as part of the patient-clinician dis-
cussion regarding the potential beneﬁts of statin
therapy and not the sole determinant of whether a
prescription is written. The use of the risk estimator
serves as the beginning of such a discussion, not the
end. It should be noted that the risk estimator may
overpredict events in Hispanic and East-Asian men
and women. Clinical judgment is particularly impor-
tant for patients where the RCT evidence is insufﬁ-
cient for guiding clinical recommendations. These
patients may be younger adults (<40 years of age)
who have a low estimated 10-year ASCVD risk, but
¶See reference 2 for tables 6 and 8.
¶
¶
FIGURE 1 Summary of Recommendations
Key recommendations for the treatment of blood cholesterol to reduce ASCVD risk in adults. Reprinted with permission from Stone et al. (2)
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CENTRAL ILLUSTRATION Statin Initiation
This illustration presents a summary of groups for statin initiation for the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) risk in
adults. ABI ¼ ankle-brachial index; CAC ¼ coronary artery calcium; hs-CRP ¼ high-sensitivity C-reactive protein; LDL-C ¼ low-density lipoprotein cholesterol.
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single strong factor or multiple risk factors. Other
groups that deserve consideration include those
with serious comorbidities and increased ASCVD
risk. Examples include those patients with humanimmunodeﬁciency virus, with rheumatologic or in-
ﬂammatory diseases, or who have undergone solid
organ transplantation. Here, the elements of the
clinician-patient discussion weighing treatment of all
risk factors, adherence to an optimal lifestyle, the
FIGURE 2 High-, M
The therapies were u
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against the potential for adverse effects and drug–
drug interactions, and informed patient preference
can guide therapeutic decisions.
When a quantitative risk decision regarding the
initiation of therapy is uncertain, the expert panel
recommends that other factors be considered.
These additional factors include: family history of
premature ASCVD with onset <55 years of age in a
ﬁrst-degree male relative or <65 years of age in a
ﬁrst-degree female relative; low-density lipoprotein
(LDL) $160 mg/dl; coronary artery calcium (CAC)
score $300 Agatston units or >75th percentile for
age, sex, and ethnicity (10); high-sensitivity C-reactive
protein (hsCRP) $2.0 mg/l; or ankle-brachial index
(ABI) <0.90. A family history of ASCVD or LDL
$160 mg/dl is most useful in younger individuals,
whereas the ABI, hsCRP, and CAC are generally
useful in older individuals. A 30-year or lifetime
risk estimation in those individuals 20 to 59 years
of age is especially useful for emphasizing lifestyle
change. The ACC/AHA risk estimator can be down-
loaded from either the ACC (11) or from the AHA
website (12).
The risk estimator includes information on the
lifestyle and obesity guidelines and provides deci-
sion support after data are entered. This allows
for more informed patient preference in primary
prevention. Thus, the clinician-patient discussion
embraces 4 areas: 1) estimation of 10-year risk (or
lifetime risk, if appropriate) and review of treatable
risk factors such as hypertension and cigarette
smoking; 2) need for adherence to an improvedoderate-, and Low-Intensity Statin Therapy
sed in the RCTs reviewed by the expert panel. Reprinted with permission frohealthy lifestyle; 3) the potential for beneﬁt in
contrast to the potential for adverse effects and/or
drug–drug interactions of statin therapy; and 4)
informed patient preference.
No evidence from RCTs to support the use
of LDL-C or non–HDL-C goa ls . As noted earlier,
CQ1 focused on RCT evidence supporting the use of
LDL-C goals to guide cholesterol-lowering therapy.
Whereas this approach is supported conceptually
by extrapolation of data from observational studies
and RCTs, there are no direct data from RCTs
that conﬁrm the efﬁcacy of using LDL-C or non–
HDL-C goals for therapy. For example, there is no
RCT evidence to support that titrating to a goal of
LDL-C <70 mg/dl improves outcomes over treating
to a goal of LDL-C <80 mg/dl. Furthermore, no
evidence was found from RCTs to support improved
clinical outcomes resulting from the addition of a
nonstatin drug to a statin to further lower LDL-C to
an arbitrary target goal. Thus, the expert panel was
unable to make any evidence-based recommenda-
tions about the use of treatment goals to guide
therapy.
Appropr ia te dose and recommendat ions for
stat in therapy . Review of evidence from RCTs
conﬁrmed a strong and consistent reduction in
ASCVD clinical events for those patients who were
treated with 3-hydroxy-3-methylglutaryl-conenzyme
A reductase (statin) therapy. Improved clinical out-
comes occurred when statin therapy was started at
LDL-C levels as low 70 mg/dl for both primary and
secondary prevention of ASCVD. Two meta-analyses
of large studies (13,14) published after completion ofm Stone et al. (2).
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these outcomes and the beneﬁts of statin therapy.
The results of RCTs show that statin therapy can be
categorized on the basis of the dose and speciﬁc statin
as high intensity, moderate intensity, or low intensity
(Fig. 2). The RCT evidence demonstrates that, for
patients <75 years of age, high-intensity statin ther-
apy consistently reduces ASCVD events more than
moderate-intensity statin therapy. Fewer patients
>75 years of age were included in the RCTs. For these
patients, although there was evidence of an addi-
tional reduction of ASCVD events from high- versus
moderate-intensity statin therapy, for safety reasons
(including increased comorbidities and potential for
side effects in the elderly) the expert panel recom-
mended that moderate-intensity statin therapy be
considered for patients >75 years of age with clinical
ASCVD. In essence, the expert panel acknowledges
that “lower is better” but recommends proven ther-
apy that is both tolerated and safe. The expert panel
recommendations for treatment are summarized in
Figure 1 and the Central Illustration.
Monitor ing and safety of stat in therapy . The
evidence from RCTs supporting the safety of statin
use was judged to be strong when used as recom-
mended in properly-selected patients with regular
follow-up assessments. Patient characteristics iden-
tiﬁed from RCTs that may inﬂuence statin safety
include: multiple or serious comorbidities, such as
impaired renal or hepatic function; a history of
previous statin intolerance or muscle disorders;
concomitant use of drugs affecting statin meta-
bolism; a history of hemorrhagic stroke; and age
>75 years. Myopathy (0.01 excess cases per 100) and
hemorrhagic stroke (0.01 excess cases per 100) make
minimal contributions to excess risk from statin
therapy (13). The expert panel did not ﬁnd evidence
from RCTs that statins adversely affect either cogni-
tive changes or risk of dementia. It was noted that
Asian ancestry might be a consideration in the initial
choice of statin intensity.
Routine measurement of creatine kinase is not
recommended. It is recommended that creatine ki-
nase be obtained as a baseline test in those at
increased risk of adverse of muscle events and in
those on statin therapy who develop muscle symp-
toms (12). Patients should be asked about muscle
symptoms when starting statin therapy and at each
subsequent visit. Baseline measurement of trans-
aminase (alanine transaminase) levels should be
performed before initiation of statin therapy and
measured during therapy if symptoms suggestive of
hepatotoxicity develop, but should not be measured
routinely.Although treatment to a target LDL-C goal is not
given a recommendation, a fasting lipid panel is rec-
ommended prior to starting and 4 to 12 weeks after
initiating therapy. The percent reduction in LDL-C
should not be used as a treatment goal or a perfor-
mance measure, but can provide useful information
about a patient’s adherence to medical therapy
and lifestyle recommendations. If LDL-C is <40 mg/dl
on 2 consecutive measurements, decreasing the
dose of statin therapy may be considered. This re-
commendation is derived from the protocol for 2
RCTs, although it should be noted that no data
have been identiﬁed to suggest that adverse events
occurred when LDL-C was <40 mg/dl.
Review of the RCT evidence base indicates that
statin therapy modestly increases the risk for devel-
oping type 2 diabetes. However, in patients taking
high-intensity statins for secondary prevention or for
primary prevention with a 10-year ASCVD risk $7.5%,
the reduction in risk for ASCVD far outweighs the
risk of diabetes. For patients on moderate-intensity
statins, the risk reduction beneﬁts outweigh the
excess risk of diabetes even down to a 10-year ASCVD
risk $5%. The rate of excess diabetes generally occurs
in those with diabetes risk factors and varies by statin
intensity. The risk is lower for moderate-intensity
statins (approximately 0.1 excess case of diabetes
per 100 statin-treated patients/year) than for high-
intensity statins (approximately 0.3 excess case of
diabetes per 100 statin-treated patients/year).
IMPLICATIONS AND OBSERVATIONS. The 2013 ACC/
AHA Guideline on the Treatment of Blood Choles-
terol to Reduce Atherosclerotic Cardiovascular Risk
in Adults (2) represents a signiﬁcant paradigm
change in the treatment of blood cholesterol to
reduce ASCVD events in both secondary prevention
and in carefully-selected primary prevention pa-
tients. A systematic review of the RCT evidence base
clearly establishes patient beneﬁts on the basis of
hard ASCVD clinical outcomes that result from
varying intensities of statin therapy. The panel did
recommend nonstatin therapies of proven beneﬁt in
the 3 high-risk groups if optimal statin therapy was
not tolerated or if it resulted in lipid lowering less
than the recommended statin class would indicate.
The use of nonstatin medical therapies without
RCT evidence of improved clinical outcomes to ach-
ieve target LDL-C treatment goals cannot be re-
commended using the current RCT evidence base.
Further research is needed to conﬁrm the incre-
mental beneﬁts of nonstatin therapies and the value
of speciﬁc LDL-C or non HDL-C goals for patient care.
The RCT systematic review provides strong evi-
dence that additional patients beneﬁt from statin
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for primary prevention. To assist in identifying
these additional patients, a new risk estimator, which
includes stroke (nonfatal and fatal) and African-
American patients, has been developed. If a quan-
titative risk decision cannot be made, additional
factors may be considered, including family history
of premature ASCVD; LDL-C $160 mg/dl; hsCRP
$2.0 mg/l; CAC score $300 Agatston units or 75th
percentile on the basis of race, age, and sex; and
ABI <0.9. A 30-year or lifetime risk estimation in those
patients 20 to 59 years of age is especially useful for
emphasizing lifestyle change. A heart-healthy life-
style remains the foundation for preventing ASCVD
and must be part of all efforts to improve ASCVD risk
factors and outcomes.
There is a need for additional RCT evidence
regarding effective strategies to reduce ASCVD risk
in women, in patients >75 and <40 years of age, and
in those of additional ethnic groups (e.g., East Asian,
South Asian and Hispanic). RCTs are needed to
conﬁrm hard clinical outcomes for nonstatin thera-
pies. RCT conﬁrmation of the efﬁcacy of the new risk
estimator and associated primary prevention strate-
gies is needed to provide a foundation for future
treatment strategies.
Guidelines, including the new 2013 ACC/AHA
Blood Cholesterol Treatment Guideline, inform, but
do not replace, clinical judgment. The current evi-
dence base must be combined with clinical judgment
and patient preference to achieve optimal care and
reduce ASCVD risk.
CHOLESTEROL GUIDELINES:
NEGOTIATING THE UNCERTAINTIES
Scott M. Grundy, MD, PhD
Three leading causes of ASCVD are hypercholester-
olemia, hypertension, and cigarette smoking. Over 3
decades ago, demonstration of risk reduction through
RCTs led the NHLBI to initiate national education
programs for high blood cholesterol and high blood
pressure. Many subsequent RCTs have conﬁrmed
clinical beneﬁts from the lowering of these 2 risk
factors (15,16). Other factors associated with ASCVD
risk are diabetes, obesity, physical inactivity, family
history of ASCVD, and various proinﬂammatory and
prothrombotic factors. Although all of these factors
are risk-associated, prevention of ASCVD through
therapeutic intervention has yet to be shown.
LDL is the dominant cholesterol-carrying lipopro-
tein. It is measured routinely as LDL-C. The mostdramatic demonstration of atherogenicity of LDL
comes from familial hypercholesterolemia (FH).
Elevated LDL-C results from a deﬁciency in hepatic
LDL receptors (17). In heterozygous FH, serum LDL-C
is elevated about 2-fold; with homozygous FH, LDL-C
is at least 4 times increased. FH patients commonly
develop premature ASCVD, which can occur even
without concomitant risk factors.
In population studies, it is apparent that elevated
LDL-C (typically reﬂected in high total cholesterol)
underlies ASCVD. Cross-country comparisons show
that populations with relatively elevated LDL-C
manifest higher rates of ASCVD than do those with
lower concentrations (18). Within populations, pa-
tients with higher cholesterol levels have greater
ASCVD rates than those with lower concentrations,
even after adjusting for other factors (18,19).
Concurrently, over the past 4 decades, numerous
RCTs have documented a reduction of ASCVD from
cholesterol-lowering therapies (20,21). Earlier RCTs
utilized nonstatin treatment. The more robust of
these demonstrated beneﬁt, but stronger evidence of
beneﬁt was uncovered through meta-analysis of all
trials (20). Subsequently, single RCTs with statins
and meta-analysis of multiple-statin trials conﬁrmed
a marked reduction of ASCVD from highly efﬁcacious
cholesterol lowering (21).
Although LDL is the dominant atherogenic lipo-
protein, very-low-density lipoproteins seem to also
promote atherosclerosis. Combining LDL-C and very-
low-density lipoprotein cholesterol into a single
target (non–HDL-C) may thus be preferable to tar-
geting LDL-C alone. In support, a recent meta-analysis
of statin trials found that non-HDL-C is more closely
correlated with ASCVD risk than LDL-C (22). Hence,
“cholesterol-lowering therapy” can apply to both
LDL-C and/or non–HDL-C.
Epidemiological studies demonstrate a contin-
uous relationship between cholesterol levels and
ASCVD risk, from low to high (18). RCTs show
the reverse: the more LDL-C is lowered, the greater
the risk reduction (23,24). These ﬁndings imply “the
more, the better” is true for cholesterol lowering.
Furthermore, there appears to be no limit beneath
which a lower LDL-C fails to reduce risk (25). Meta-
analysis of statin trials show that risk reduction
extends into the very low range for LDL-C. Thus, it
can be said that “the lower, the better” is true for
cholesterol reduction. Genetic epidemiology adds
another dimension; persons having a lifetime of low
cholesterol levels manifest a particularly low prev-
alence of ASCVD (26). This ﬁnding indicates that
“the longer, the better” is true for cholesterol
TABLE 1 Categories of LDL-C and Non–HDL-C
Cholesterol Category
LDL-C Level,
mg/dl
Non-HDL-C Level,
mg/dl
Very high $175 $200
High 150–174 175–199
Borderline high 125–149 150–174
Borderline low 100–124 125–149
Low 75–99 100–124
Very low 50–74 75–99
Range of cholesterol categories, on the basis of the guidelines.
HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein
cholesterol.
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LDL-C and non–HDL-C ranges according to relative
risk for ASCVD. These ranges come from a meta-
analysis of statin trials (25).
RCTs reveal that, regardless of the modality of
cholesterol lowering, ASCVD risk is diminished. This
is true for diet, bile acid resins, ileal-exclusion oper-
ation, ﬁbrates, nicotinic acid, and statins (15,20,21).
The degree of risk reduction depends on the extent of
lowering, not on the therapeutic modality. Statins
lower LDL-C by 35% to 55%, depending on the type
and dose; ileal exclusion, which is rarely used, re-
duces LDL-C by 30% to 35%; and bile acid resins,
nicotinic acid, and ﬁbrates decrease LDL-C by 10%
to 20%. A newer drug, ezetimibe, lowers LDL-C by
15% to 20%. Dietary therapy adds an additional 5% to
15% lowering. Because of high efﬁcacy and tolera-
bility, statins have emerged as ﬁrst-line therapies.
Other cholesterol-lowering drugs are generally
reserved for patients who are statin-intolerant or as
add-ons to statins to enhance cholesterol reduction.
Unfortunately, the clinical beneﬁt from combined
drug therapy has not been adequately explored
through RCTs.
Because FH patients can develop full-blown
ASCVD in the absence of other risk factors, there is
little doubt that elevated LDL-C is atherogenic.
Population and genetic studies further disclose that
without some elevation of LDL-C, cigarette smoking,
hypertension, and diabetes cause little coronary
heart disease (26,27). We might conclude, therefore,
that elevated LDL is the prime driver of atherogen-
esis, whereas other risk factors worsen athero-
sclerosis or precipitate its complications. If true,
treatment of these accelerating risk factors should
probably be accompanied by cholesterol-lowering
therapy.
There is almost universal agreement that patients
with established ASCVD should receive cholesterol-
lowering drugs. This consensus is supported bysingle RCTs and by meta-analysis (23–25). High
doses of statins usually are required for maximized
cholesterol lowering. Ideally, LDL-C and non–HDL-C
should be reduced to very low levels (Table 1). Yet,
many patients cannot achieve these very low levels,
even with high doses of powerful statins (25).
Should a second cholesterol-lowering drug be added
in such patients? One clinical trial failed to
demonstrate added efﬁcacy when niacin was com-
bined with maximal statin therapy (28). Additional
LDL-C lowering with niacin was modest. Another
secondary prevention study is currently comparing
high-dose simvastatin with the same drug plus
ezetimibe. The latter agent is expected to add
another 15% to 20% of LDL-C lowering. Whether
ezetimibe plus high-dose statin is more efﬁcacious
than the high-dose statin alone remains to be seen.
A newer class of drugs, called PCSK9 inhibitors,
powerfully reduces LDL-C; PCSK9 inhibitors are
currently being tested to determine how much
additional risk reduction occurs when combined
with high doses of statins (29).
Primary prevention with cholesterol-lowering
drugs is a more complex issue than secondary pre-
vention. A few examples can be considered.
Most researchers support intensive cholesterol
lowering in patients with type 2 diabetes, even in the
absence of ASCVD (2). These patients carry a high risk
for future ASCVD, and risk reduction with statin
therapy has been clearly documented. Furthermore,
when patients with diabetes have concomitant
metabolic syndrome, their ASCVD risk is substantially
raised (30). Consequently, it is reasonable to lower
LDL-C in patients with metabolic syndrome, as well
as in those with diabetes.
Cigarette smoking is another factor that confers
high lifetime risk for ASCVD. That statins reduce
cardiovascular events in smokers has been amply
documented (21). Thus, middle-aged and older
smokers are good candidates for statin treatment. The
same can be said for older persons with poorly-
controlled hypertension. Whether to utilize a statin
in patients with well-controlled hypertension as the
only risk factor is a matter of clinical judgment. For
persons who are smokers only or who only have hy-
pertension, reducing LDL-C levels to a low range may
be sufﬁcient (Table 1). But, for those with both risk
factors, lowering LDL-C to a very low range is
reasonable (31).
The ACC/AHA (5) recently published a 10-year risk
algorithm for ASCVD on the basis of major risk fac-
tors. At the same time, the ACC/AHA (26) recom-
mended that statin therapy be instituted in persons
with a 10-year risk for ASCVD $7.5%. Older persons
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mostly exceed the treatment threshold, and accord-
ingly, are recommended for statin treatment. In this
age range, the presence of a single risk factor confers
a 10-year risk of approximately 15% by the algorithm
(5). Here statins seem reasonable. A 10-year risk
of $15% because of multiple borderline risk factors is
equivalent to a single major risk factor; likewise, at
this level of risk, statin therapy in older persons is
sound.
Whether to initiate statin therapy in older persons
whose calculated 10-year risk for ASCVD is 7.5% to
15% is a matter of clinical judgment. This is particu-
larly true in the light of the claim that the ACC/AHA
algorithm substantially overestimates the 10-year risk
for the current U.S. population (32).
An underused modality for risk assessment in older
persons is the CAC score. ACC/AHA guidelines
contend that a high CAC score (e.g., $300 Agatston
units) confers a high-enough risk to initiate statin
therapy (2). Persons with low CAC and a paucity of
major risk factors are at low risk and are not good
candidates for cholesterol-lowering drugs (33). CAC
measurement is a more reliable indicator of risk than
chronological age (34). Older patients with a 10-year
risk of 7.5% to 15% who have CAC scores in the
range of 100 to 299 are in a borderline zone, making
cholesterol-lowering drugs optional. In this range,
additional risk indicators may be useful for guidance
of therapy. At lower CAC scores in otherwise low-risk
individuals, 10-year risk is low and statin therapy is
not necessary.
For 2 reasons, the AHA/ACC algorithm should be
more reliable in middle-aged adults (age 40 to
65 years) than in older persons. First, in this age
range, estimated risk depends more on major risk
factors than on age; and second, for any estimated
risk, lifetime risk is higher in middle-aged adults than
in elderly patients. Therefore, using a 7.5% risk
threshold for initiating statin therapy is more
reasonable for middle-aged adults than for older
persons. But, lifestyle intervention should not be
ignored; it has greater potential for long-term risk
reduction when started at a younger age. Indeed, for
younger people (age <40 years), priorities for pre-
vention should be given to lifestyle change.
The ACC/AHA (2) recommended starting statin
therapy in anyone with an LDL-C $190 mg/dl, even in
the absence of other risk factors. Because a lifetime of
elevated LDL-C carried a high risk, the use of statins
in patients whose LDL-C is consistently over 160
mg/dl seems reasonable.
CRITIQUE OF THE ACC/AHA GUIDELINES. The ACC/
AHA guidelines describe themselves as an effort toapply strict “evidence-based” rules to the complex
topic of cholesterol management. The cholesterol
panel adhered more rigidly to perceived rules than did
the blood pressure panel working under the same
mandate. For example, the cholesterol panel could
identify no therapeutic goals for cholesterol lowering,
whereas the blood pressure panel was able to set goals
even though the strength of the evidence was similar
for the 2 risk factors. A lack of cholesterol goals leaves
the physician in the dark for setting an individualized
statin dose and evaluating the adequacy of the risk
reduction from therapy. This is less helpful than the
approach taken by the blood pressure panel.
The cholesterol panel stressed restriction of
guideline development to data from RCTs. Still, they
resorted to epidemiological data when establishing
the all-important basis for who should be treated
with cholesterol-lowering drugs, namely, global risk
assessment. In middle-aged individuals, a mix of
major risk factors is required to justify statin therapy.
Importantly, age is generally not the dominant risk
factor. But in older populations, age becomes the
dominant risk factor; at the same time, age loses its
reliability as a risk factor when applied to patients.
The most problematic result of deriving a uniform
risk threshold for drug treatment from population-
based data, regardless of age, is that almost all older
people will require statin therapy, even though a
signiﬁcant number of them are virtually free of major
risk factors and underlying atherosclerosis. Conse-
quently, a high number of very low-risk persons of
advancing age will be treated unnecessarily. To avoid
overtreatment of older persons, either a higher risk
threshold must be set or imaging modalities must be
used to distinguish between higher- and lower-risk
patients.
The cholesterol panel was left in the awkward po-
sition of having to relegate cholesterol-lowering life-
style therapies to another panel, which did not use
the same “evidence-based” approach. RCT evidence
for lifestyle intervention is largely lacking, but
epidemiological evidence of the beneﬁt of certain
lifestyle patterns is strong. Previous cholesterol
guidelines stressed lifestyle intervention as the
foundation of cholesterol management. By removing
this priority from the cholesterol guidelines, they are
transformed largely into statin treatment guidelines.
This conveys an unfortunate message to caregivers,
particularly in the area of primary prevention.
It is curious that the new guidelines failed to
discuss the metabolic syndrome, even though the
AHA and NHLBI have placed great emphasis on this
syndrome as a major multiplex risk factor for ASCVD.
Thanks in no small part to these 2 organizations, the
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diovascular community and has enhanced the op-
portunity to highlight lifestyle intervention in the
prevention of ASCVD.
Finally, the purpose of cholesterol guidelines is to
assist physicians in the management of patients at
risk. However, the guidelines, as written, effectively
apply a public health strategy rather than a clinical
strategy by recommending standard doses of statins
using evidence derived from RCTs, in which the
average participant had a risk similar to the patient’s
risk. This shortcoming appears to be an unfortunate
result of the panel’s misapplication of the so-called
evidence-based approach. Almost as an after-
thought, the concluding statement of the ﬁrst sectionof this article states: “The current evidence base must
be combined with clinical judgment and patient
preference to achieve optimal care and reduce ASCVD
risk.” However, virtually no guidance is provided to
the caregiver for how to adjust the guidelines to best
ﬁt the patient.
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